Hypoxia-Specific Metal–Organic Frameworks Augment Cancer Immunotherapy of High-Intensity Focused Ultrasound
Source abstract
Abstract
As a noninvasive treatment modality, high-intensity focused ultrasound (HIFU)-induced antitumor immune responses play a vital role in surgery prognosis. However, limited response intensity largely hinders postoperative immunotherapy. Herein, a hypoxia-specific metal–organic framework (MOF) nanosystem, coordinated by Fe 3+, hypoxic-activated prodrug AQ4N, and IDO-1 signaling pathway inhibitor NLG919, is developed for the potentiating immunotherapy of HIFU surgery. The loaded AQ4N enhances the photoacoustic imaging effects to achieve accurate intraoperative navigation. Within the HIFU-established severe hypoxic environment, AQ4N is activated sequentially, following which it cooperates with Fe 3+ to effectively provoke immunogenic cell death. In addition, potent NLG919 suppresses IDO-1 activity and degrades the immunosuppressive tumor microenvironment aggravated by postoperative hypoxia. In vivo studies demonstrate that the MOF-mediated immunotherapy greatly inhibits the growth of primary/distant tumors and eliminates lung metastasis. This work establishes a robust delivery platform to improve immunotherapy and the overall prognosis of HIFU surgery with high specificity and potency.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Ultrasound and Hyperthermia Applications · Photoacoustic and Ultrasonic Imaging
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, 400016 Chongqing, P. R. China
Funding
National Natural Science Foundation of China
References (36)
Show source-provided references
1. 10.1016/S1470-2045(22)00251-010.1016/S1470-2045(22)00251-0 ↗
2. 10.1016/j.eururo.2022.01.00510.1016/j.eururo.2022.01.005 ↗
3. 10.7150/thno.4283010.7150/thno.42830 ↗
4. 10.7150/thno.1347810.7150/thno.13478 ↗
5. 10.1016/j.pharmthera.2023.10839310.1016/j.pharmthera.2023.108393 ↗
6. 10.1016/j.apsb.2021.07.02510.1016/j.apsb.2021.07.025 ↗
7. 10.1158/1078-0432.CCR-19-160410.1158/1078-0432.CCR-19-1604 ↗
8. 10.1038/s41571-019-0319-910.1038/s41571-019-0319-9 ↗
9. 10.1002/adma.20200763010.1002/adma.202007630 ↗
10. 10.1007/s00262-016-1891-910.1007/s00262-016-1891-9 ↗
11. 10.1136/jitc-2022-00622610.1136/jitc-2022-006226 ↗
12. 10.1021/acsnano.3c0623310.1021/acsnano.3c06233 ↗
13. 10.1021/acsnano.2c0046210.1021/acsnano.2c00462 ↗
14. 10.1016/S0301-5629(01)00515-410.1016/S0301-5629(01)00515-4 ↗
15. 10.1158/1078-0432.CCR-16-089510.1158/1078-0432.CCR-16-0895 ↗
16. 10.1054/bjoc.2000.156410.1054/bjoc.2000.1564 ↗
17. 10.1002/adhm.20220234810.1002/adhm.202202348 ↗
18. 10.1002/adma.20170763410.1002/adma.201707634 ↗
19. 10.1039/D0CS00883D10.1039/D0CS00883D ↗
20. 10.1021/acsnano.2c1025110.1021/acsnano.2c10251 ↗
21. 10.1038/s41571-021-00539-410.1038/s41571-021-00539-4 ↗
22. 10.1186/s13045-022-01292-610.1186/s13045-022-01292-6 ↗
23. 10.1136/jitc-2020-00100810.1136/jitc-2020-001008 ↗
24. 10.1016/j.trecan.2017.11.00510.1016/j.trecan.2017.11.005 ↗
25. 10.1186/s13045-021-01080-810.1186/s13045-021-01080-8 ↗
26. 10.1002/adma.20230726310.1002/adma.202307263 ↗
27. 10.1002/adma.20210218810.1002/adma.202102188 ↗
28. 10.1002/adhm.20210231510.1002/adhm.202102315 ↗
29. 10.1002/adma.20190405810.1002/adma.201904058 ↗
30. 10.1002/adma.20190726710.1002/adma.201907267 ↗
31. 10.1038/s41590-022-01132-210.1038/s41590-022-01132-2 ↗
32. 10.1038/nrc338010.1038/nrc3380 ↗
33. 10.1002/smll.20230343810.1002/smll.202303438 ↗
34. 10.1021/acs.nanolett.3c0338210.1021/acs.nanolett.3c03382 ↗
35. 10.1126/science.aaf215410.1126/science.aaf2154 ↗
36. 10.1016/j.it.2016.01.00210.1016/j.it.2016.01.002 ↗